nafagrel has been researched along with Cardiovascular Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iimura, O; Iwamoto, T; Miura, T; Ogawa, T; Shimamoto, K; Tsuchida, A | 1 |
| Endoh, A; Iimura, O; Iwamoto, T; Miura, T; Ogawa, T; Tsuchida, A; Urabe, K | 1 |
2 other study(ies) available for nafagrel and Cardiovascular Stroke
| Article | Year |
|---|---|
Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Topics: Animals; Constriction; Coronary Vessels; Disease Models, Animal; Heparin; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; Rabbits; Tetrahydronaphthalenes; Thromboxane A2; Thromboxane-A Synthase | 1991 |
Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
Topics: Animals; Blood Pressure; Drug Therapy, Combination; Heart; Heart Rate; Imidazoles; Myocardial Infarction; Myocardial Reperfusion Injury; Rabbits; Tetrahydronaphthalenes; Thromboxane-A Synthase; Tissue Plasminogen Activator | 1990 |